Stay updated with breaking news from Affect Plasma Concentrations. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Analysis from a 10-month post-launch evaluation of the REMS Program finds 2.8% incidence of LVEF ...
Results from VALOR-HCM LTE demonstrated that with longer follow-up, CAMZYOS continued to reduce eligibility for invasive SRT at 56 weeks EXPLORER-LTE data showed sustained improvements in LVOT...
New analyses, including late-breaking data and presentations on CAMZYOS® and Eliquis® , reaffirm the company's steadfast dedication to tackling cardiovascular diseases ...
PRINCETON, N.J.--(BUSINESS WIRE)--Jun 26, 2023--
CAMZYOS is the first and only cardiac myosin inhibitor approved in the European Union Approval based on two positive Phase 3 trials, EXPLORER-HCM and VALOR-HCM, demonstrating significant benefit in patients treated with CAMZYOS versus placebo